Journals / Türk Biyokimya Dergisi / 2009 / Cilt: 34 - Sayı: 2

İdiyopatik parkinson hastalarında mitokondriyel solunum zinciri enzim aktiviteleri, mtDNA variantları ve gen ekspresyon düzeyleri

Mitochondrial respiratory chain enzyme activities, mtDNA variants and gene expression levels in idiopathic parkinson’s disease

Pages
97–104
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

ND2 (19 % and 21 %) and ND4 (14 % and 13 %) mRNA expressions were reduced in two of 19 patients.Conclusion: Taken together, Complex I and IV dysfunctions and mitochondrial abnormalities might be the result of oxidative stress contributing to the pathogenesis of idiopathic Parkinson’s Disease since we found that reduced glutathione levels were decreased 47 % in thesepatients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Mitochondrial dysfunction has been implicated in the development of idiopathicParkinson’s disease.
📊
Key Findings & Data:In this study, it was aimed to investigate the relationship between mi- tochondrial respiratory chain enzyme deficiency and variants in ND2 and ND4 region ofComplex I and expressions of these genes.
💡
Conclusion & Impact:ND2 (19 % and 21 %) and ND4 (14 % and 13 %) mRNA expressions were reduced in two of 19 patients.Conclusion: Taken together, Complex I and IV dysfunctions and mitochondrial abnormalities might be the result of oxidative stress contributing to the pathogenesis of idiopathic Parkinson’s Disease since we found that reduced glutathione levels were decreased 47 % in thesepatients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: Mitochondrial dysfunction has been implicated in the development of idiopathicParkinson’s disease. In this study, it was aimed to investigate the relationship between mi- tochondrial respiratory chain enzyme deficiency and variants in ND2 and ND4 region ofComplex I and expressions of these genes. Complex IV activity and glutathione level werealso studied. Methods: Activities of Complex I, Complex IV, citrate synthase and glutathione levels weremeasured from muscle biopsy samples of 19 idiopathic Parkinson’s Disease patients. EntireND2 and ND4 regions of Complex I were screened by sequencing and expression levels ofthese regions were also examined by using relative quantitative RT-PCR. Results: A significant decrease in Complex I and IV activities was found in Parkinson’sDisease patients (19.73 ± 8.24 U/mg protein, 11.51 ± 6.45 U/mg protein) compared with thecontrol group (31.48 ± 8.28 U/mg protein, 30.02 ± 14.76 U/mg protein), respectively. Althoughseveral sequence variants were detected in ND2 and ND4 genes, they didn’t account for thedecrease in Complex I activity. ND2 (19 % and 21 %) and ND4 (14 % and 13 %) mRNA expressions were reduced in two of 19 patients.Conclusion: Taken together, Complex I and IV dysfunctions and mitochondrial abnormalities might be the result of oxidative stress contributing to the pathogenesis of idiopathic Parkinson’s Disease since we found that reduced glutathione levels were decreased 47 % in thesepatients.

Özet

Amaç: İdiyopatik Parkinson Hastalığı’nın ortaya çıkmasında mitokondriyel bozukluk oldukça önemlidir. Çalışmada mitokondriyel solunum zinciri enzim hasarı ile Kompleks I’in ND2ve ND4 bölgelerindeki varyantlar ve bu genlerin ekspresyon düzeyleri arasındaki ilişkininincelenmesi amaçlandı. Ayrıca Kompleks IV aktivitesi ile glutatyon düzeyleri değerlendirildi. Yöntem: Kompleks I, Kompleks IV ve sitrat sentaz enzim aktivitelerini tayin etmek amacıyla 19 idiyopatik Parkinson hastasından elde edilen kas biyopsi örnekleri kullanıldı. AyrıcaKompleks I’in ND2 ve ND4 bölgeleri sekanslama yapılarak tarandı ve bu bölgelerin ekspresyon düzeylerine göreceli kantitatif RT-PCR yöntemiyle bakıldı. Bulgular: İdiyopatik Parkinson Hastaları’nda Kompleks I (19.73 ± 8.24 U/mg protein) veKompleks IV (11.51 ± 6.45 U/mg protein) aktivitelerinde kontrol grubuna (31.48 ± 8.28 U/mgprotein, 30.02 ± 14.76 U/mg protein) kıyasla belirgin azalma gözlendi. Sekanslama sonucun- da ND2 ve ND4 gen dizilerinde birçok sekans varyantı bulunmasına karşılık bunların Kompleks I aktivitesindeki düşüşten sorumlu olmadığı düşünüldü. Yine bu genlerin ekspresyondüzeylerine bakıldığında 19 hastadan sadece iki tanesinde Kompleks I’de % 19 ve % 21’lik;Kompleks IV’de ise % 14 ve % 13’lük azalma saptandı.Sonuçlar: Bütün bu sonuçlar ve hasta grubun glutatyon düzeyindeki % 47’lik düşüş dikkatealındığında Kompleks I ve IV’ün hasarı ve mitokondriyel bozukluklar oksidatif stresin sonucu olabilmekte ve Parkinson Hastalığı’nın ortaya çıkmasına katkıda bulunabilmektedir.

🔖

Cite This Article

ERCAN, A., KULAKSIZ, G., MÜFTÜOĞLU, M., ÖZER, N., OGUS, H., DALMIZRAK, Ö., ÇAVDAR, L., İNAN, L. (2022). İdiyopatik parkinson hastalarında mitokondriyel solunum zinciri enzim aktiviteleri, mtDNA variantları ve gen ekspresyon düzeyleri. Türk Biyokimya Dergisi, Cilt: 34 - Sayı: 2, 97–104. https://ajindex.com/articles/618174

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sun F, Kanthasamy A, Anantharam V, Kanthasamy AG. (2007) Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson’s disease. Pharmacology & Therapeutics. 114: 327-344
  2. Riess O, Jakes R, Krüger R. (1998) Genetic dissection of familial Parkinson’s disease. Molecular Medicine Today. 4: 438-444
  3. Thomas B, Beal MF. (2007) Parkinson’s Disease. Human Molecular Genetics. 16: 183-194
  4. Schapira AHV (2007) Mitochondrial dysfunction in Parkinson’s disease. Cell Death and Differentiation (2007) 14, 1261–1266
  5. Mizuno Y, Yoshino H, Ikebe S, Hattori H, Kobayashi T. Shimodo-Matsubayashi S, Matsumine H. & Kondo T. (1998) Mitochondrial dysfunction in Parkinson’s Disease. Ann. Neurol. 44: S99-S109
  6. Davis GC, Williams AC, Markey SP, Ebert MH, Calne CD, Riechert CM, Kopin IJ. (1979) Chronic parkinsonism secondary to intravenous of meperidine analogues. Psychiatry Res. 1: 649-654
  7. Langston JW, Ballard P, Tetrud JW, Irwin J. (1983) Chronic parkinsonism in humans due to a product of meperidine analog synthesis. Science. 219: 979-980
  8. Shadel GS, Clayton DA. (1997) Mitochondrial DNA maintenance in vertebrates. Annu Rev Biochem. 66: 409-435
  9. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. (2001) Complex I and Parkinson’s disease. IUBMB Life. 52: 135-141
  10. Ikebe S, Tanaka M, Ozawa T. (1995) Point mutations of mitochondrial genome in Parkinson’s disease. Mol Brain Res. 29: 281-295
  11. Benecke R, Strümper P, Weiss H. (1993) Electron transfer Complexes I and IV of platelets are abnormal in Parkinson’s disease but normal in Parkinson-plus syndromes. Brain, 116(6):1451-63
  12. Haas RH, Nasirian F, Nakano K, Ward D, Pay M, et al (1995). Low mitochondrial Complex I and Complex II/III activity in early untreated Parkinson’s disease. Ann Neurol. 37:714-722
  13. Cardellach F, Marti MJ, Fernandez-Sola J, Marin C, Hoek JB, Tolosa E, Urbano-Marquez A. (1993) Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson’s disease. Neurology. 43: 2258-2262
  14. Muftuoglu M, Elibol B, Dalmizrak O, Ercan A, Kulaksiz G, Ogus H, Dalkara T, Ozer N. (2003) Mitochondrial Complex I and IV activities in leukocytes from patients with parkin mutations. Movement Disorders. 19: 544-548
  15. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD (1992). Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson’s disease. Brain. 115(2)